Next Investors logo grey

$2M in repeat purchase orders display Creso Pharma’s growth potential


Published 13-OCT-2020 13:08 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma Limited (ASX: CPH, FRA: 1X8) has once again strengthened its revenue profile with another repeat purchase order from South African-based Pharma Dynamics.

Creso’s repeat purchase orders now total more than $2 million on a year-to-date basis.

This is the second purchase order from Pharma Dynamics for CPH’s cannaQIX® product – sold under the ‘Cannamics’ brand and follows the successful product launch into the South African market in March 2020.

Pharma Dynamics will distribute Creso Pharma’s hemp-based products across South Africa, with plans to extend the distribution to Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda.

Non-Executive Chairman Mr Adam Blumenthal said of the deal, “Securing this latest purchase order with Pharma Dynamics is a significant development and highlights the multiple opportunities we are witnessing in the region. Creso Pharma is beginning to see a trend in repeat orders from its clients globally which reinforces Creso’s high quality products.”

Pharma Dynamics, a subsidiary of the $472.3BN capped Lupin Limited (NSE: LUPIN), currently ranks as the third fastest growing pharmaceutical company in South Africa, and leads the country in their supply of high-quality generics set at affordable prices.

Pharma Dynamics is well known for investments into innovative wellness programs towards holistic healthcare, with a growing range of over-the-counter products including cold and flu, allergy and immune booster products. Their products are consistently prescribed and recommended by leading doctors and pharmacists countrywide.

This successful partnership is yet another win for Creso Pharma, which as stated has received over $2M in purchase orders year-to-date.

Central to this growth has been their 100% ownership of Mernova Medical Inc. located in Nova Scotia, Canada – owner of a 24,000 square foot world-class, cannabis growing, revenue generating, Cultivation and Production Facility.

Mernova, is key to Creso Pharma’s market expansion, with part of the funds from their $8.92 million backing from institutional, professional and sophisticated investors having been earmarked for such initiatives.

Mernova Medicinal received its initial purchase order from Nova Scotia Liquor Corporation (NSLC) for the purchase of two of the group’s premium strains, HPG 13 and Lemon Haze.

The initial purchase order from Nova Scotia’s sole distributor of recreational cannabis had a value of C$180,000 (A$189,000), and the second purchase order had a value of circa $253,000. These orders from Nova Scotia display broad significance as they signalled the group’s entry into Canada’s retail markets, further diversifying Mernova’s revenue streams and adding to their growing wholesale product sales pipeline.

CPH’s growing revenue profile and international growth initiatives are further emphasised by Blumenthal: “The demand for our product on a global scale vindicates the market share initiatives we have put in place, and the recent sales in Africa and Canada shows that this strategy is not only growing the Company’s footprint but also generating significant revenue. We look forward to further capitalising on these opportunities in the near-term.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.